Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ginkgo Bioworks (DNA) Q4 Revenue Tops Consensus
March 28, 2022 4:04 PM EDTGinkgo Bioworks (NYSE: DNA) reported Q4 EPS of ($1.10), $1.06 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $148.5 million versus the consensus estimate of $94.81 million.
GUIDANCE:
Ginkgo Bioworks sees FY2022 revenue of $325-340 million, versus the... More
